LOGIN
ID
PW
MemberShip
2025-02-07 03:52
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
The era of compound management for obesity
by
Whang, byung-woo
Jan 23, 2025 05:54am
Wegovy (semaglutide), an obesity drug hailed as a game-changer, is seeking synergy with its cardiovascular benefits in addition to weight loss. Experts say that the obesity treatment paradigm is already evolving beyond weight loss to overall health care. In the future, it will be a challenge to improve access through expert review and reimbur
Policy
If atrial fibrillation develops, Rx 'Omega-3' API
by
Lee, Hye-Kyung
Jan 23, 2025 05:54am
The administration of the active ingredient 'omega-3-acid ethyl esters90,' which is used for treating dyslipidemia, will be permanently discontinued if a patient develops atrial fibrillation. Starting February 10, the Ministry of Food and Drug Safety (MFDS) will modify the approval specification based on the results of the European Medic
Policy
MFDS approves immune thrombocytopenia drug Tavalisse
by
Lee, Hye-Kyung
Jan 23, 2025 05:54am
The Ministry of Food and Drug Safety (MFDS) announced on the 20th that it has approved Tavalisse Tab 100 mg (fostamatinib sodium hydrate), an orphan drug used to treat immune thrombocytopenia in adults. Adult immune thrombocytopenia is an autoimmune disease in which antibodies against platelets are produced and platelets are destroyed in
Company
MET inhibitor Tepmetko enters last stage to reimb in KOR
by
Eo, Yun-Ho
Jan 23, 2025 05:54am
MET-targeted anticancer drug ¡®Tepmetko¡¯ has entered the final gateway to insurance reimbursement nearly 3 years after its domestic approval. According to industry sources, Merck Korea has recently started negotiating drug prices with the National Health Insurance Service for its Tepmetko (tepotinib), a treatment for locally advanced or
Company
"C-Trelin proven effective for SCD treatment¡¦reimb needed"
by
Lee, Seok-Jun
Jan 22, 2025 05:55am
There is currently no standard therapy available for 'spinocerebellar degeneration (SCD).' Doctors write prescriptions based on a patient's condition, but there are still unmet needs in 'SCD treatment.' Patients affected by disease likewise. SCD is a degenerative disease affecting the cerebellum or spinal cord due to various underlying cau
Company
"Foreign drug price re-evaluation, unfair direct comparison"
by
Kim, Jin-Gu
Jan 22, 2025 05:54am
Yunhong Noh, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), has criticized the government's re-evaluation of foreign drug price comparison. Noh points out that making a simple drug price comparison poses problem despite differences in socioeconomic circumstances and healthcare systems between South
Company
Leqembi may be prescribed in general hospitals in Korea
by
Eo, Yun-Ho
Jan 22, 2025 05:54am
The new Alzheimer¡¯s drug Leqembi is landing in general hospitals in Korea According to industry sources, Leqembi (lecanemab) has passed the drug committees (DCs) of top tertiary hospitals in Korea, such as Samsung Medical Center, Seoul Asan Medical Center, and Sinchon Severance Hospital, as well as medical institutions such as Busan Paik
Policy
MOHW to 'carefully review' post-dispensing notification law
by
Lee, Jeong-Hwan
Jan 22, 2025 05:54am
A bill to add the Health Insurance Review and Assessment Service to the post-notification subjects for dispensing substitute drugs by pharmacists is scheduled to be reviewed on the 21st, but the government's cautious stance is expected to be a hurdle. The Ministry of Health and Welfare has not changed its stance on the bill, saying it sh
Company
HK Inno.N and Roche will co-promote Avastin
by
Chon, Seung-Hyun
Jan 22, 2025 05:54am
HK Inno.N announced on the 21st that it has signed a co-promotion agreement with Roche Korea for Roche¡¯s targeted anticancer drug Avastin (bevacizumab). Avastin is an anticancer drug indicated for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, advanced or metastatic renal cell carcin
Policy
Yuyu seeks to expand the scope of its fexofenadine to ETC
by
Lee, Tak-Sun
Jan 21, 2025 05:54am
Yuyu Pharma, which developed a 60mg OTC drug containing the antihistamine fexofenadine, is now seeking to enter the specialty drug market. Currently, only Handok, the original drugmaker, and Hanmi Pharm own a 180 mg fexofenadine product, but Yuyu Pharma is expected to barge in and pave its way into the two-drug market with its new produc
1
2
3
4
5
6
7
8
9
10
>